Education
About Us
Working with TipRanks
Follow Us
Prothena (PRTA)
NASDAQ:PRTA
PRTA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.36 - $25.42
Previous CloseN/A
Volume58.73K
Average Volume (3M)1.38M
Market Cap
$354.18M
Enterprise ValueN/A
Total Cash (Recent Filing)$471.39M
Total Debt (Recent Filing)$10.84M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Aug 07, 2025EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding53,826,980
10 Day Avg. Volume1,370,212
30 Day Avg. Volume1,380,596
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)1.45
Price to Sales (P/S)0.00
P/FCF Ratio-4.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$27.67Price Target Upside504.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Prothena News
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentPRX005’s MTBR-targeting MOA is supported by recent data as a promising approach for Alzheimer’s disease treatment, reinforcing tau pathology modulation.
Partnership OpportunitiesPRX012 remains a key internal program, with plans to share initial data from the Ph1 ASCENT trial, which may drive interest from potential partners like BMS.
Therapeutic PotentialThe decision to investigate 200 mg and 400 mg doses in a once-monthly regimen reflects confidence in PRX012’s therapeutic potential.
Bears Say
Clinical Trial OutcomeThe Ph3 AFFIRM-AL trial for birtamimab in AL amyloidosis failed to meet the primary endpoint of all-cause mortality, leading to a downgrade of PRTA to Perform from Outperform and removal of the price target.
Earnings And Price TargetThe discontinuation of birtamimab has led to a reduction in the price target from $30 to $14.
Financial StabilityThere are concerns about further cash burn in a difficult capital markets environment, impacting the company's financial stability.
Ownership Overview
13.43% Insiders
30.50% Mutual Funds
0.14% Other Institutional Investors
47.67% Public Companies and Individual Investors
PRTA FAQ
What was Prothena’s price range in the past 12 months?
Prothena lowest stock price was $6.36 and its highest was $25.42 in the past 12 months.
What is Prothena’s market cap?
Prothena’s market cap is $354.18M.
When is Prothena’s upcoming earnings report date?
Prothena’s upcoming earnings report date is Aug 07, 2025 which is in 71 days.
How were Prothena’s earnings last quarter?
Prothena released its earnings results on May 08, 2025. The company reported -$1.12 earnings per share for the quarter, missing the consensus estimate of -$0.97 by -$0.15.
Is Prothena overvalued?
According to Wall Street analysts Prothena’s price is currently Undervalued.
Does Prothena pay dividends?
Prothena does not currently pay dividends.
What is Prothena’s EPS estimate?
Prothena’s EPS estimate is -1.01.
How many shares outstanding does Prothena have?
Prothena has 53,826,980 shares outstanding.
What happened to Prothena’s price movement after its last earnings report?
Prothena reported an EPS of -$1.12 in its last earnings report, missing expectations of -$0.97. Following the earnings report the stock price went up 4.648%.
Which hedge fund is a major shareholder of Prothena?
Currently, no hedge funds are holding shares in PRTA
Prothena Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.67 (504.15% Upside)
$27.67 (504.15% Upside)
Hedge Fund Trend
Decreased
By 35.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $48.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.26%
12-Months-Change
Fundamentals
Return on Equity
-23.46%
Trailing 12-Months
Asset Growth
-20.52%
Trailing 12-Months
Company Description
Prothena
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
PRTA Company Deck
PRTA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a balanced outlook for Prothena. While there are significant opportunities for growth through its robust portfolio and strategic partnerships, challenges remain, particularly with the dependency on future clinical trial successes and the narrow miss in prasinezumab's statistical significance.Read More>PRTA Stock 12 Month Forecast
Average Price Target
$27.67
▲(504.15%Upside)
Technical Analysis
Rocket Pharmaceuticals
―
KalVista Pharmaceuticals
―
Replimune Group
―
Immunome
―
Bicara Therapeutics Inc.
―